This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.
Adapted from Johnston M.I., Flores J. Progress in HIV Vaccine Development. Current Opinion in Pharmacology. 2001:1(5):504-520. On the Web at www.niaid.nih.gov/daids/vaccine/pdf/pc1506.pdf. Additional information from Science Magazine 2001 293 (5537): 1973.
As drug-resistant HIV virus becomes more and more common, physicians will need alternative methods of treating the virus. One of the most promising of these methods is the development of a prophylactic or therapeutic vaccine. The following table provides information on vaccines currently in the development pipeline.
Vaccine Name
HIV Subtype Targeted
Producing Company
Status
gp120
B/B, B/E
VaxGen
Ongoing phase III trials in the United States and Thailand
ALVAC-HIV
B, E
Aventis Pasteur
Ongoing phase II trials in the U.S., Haiti, Brazil, Trinidad (subtype B); Thailand (sub-type E); used alone or in combination with gp120
ALVAC-HIV
A
Aventis Pasteur
Ready for Phase I trials in Uganda
Lipopeptides LP5, LP6
B
ANRS: National Agency for AIDS Research, France
Ongoing phase I trials in France
Vaccinia TBC-3B
B
Therion
Ongoing phase I trials in the U.S.
DNA-HIV
B
Apolion
Completed phase I trials
DNA-HIV, MVA-HIV
A
University of Oxford
Ongoing phase I trials in the UK and Kenya
NYVAC-HIV
B
Aventis Pasteur
Ready for phase I in the U.S.
DNA-HIV, Adenovirus HIV
B
Merck
Ongoing phase I trials in the U.S.
VaxGen Canarypox with HIV gag, protease, and env +gp120
B/E
U.S. Military, Royal Thai Govt., Mahidol U., Aventis Pasteur, VaxGen
Earliest phase III start date: Summer 2002, Thailand*
Canarypox with HIV env, gag, protease, pol, and nef, +gp120
B/?
NIH HVTN, Aventis Pasteur, VaxGen
Earliest phase III start date: December 2002, U.S., Brazil, Haiti, Peru, Trinidad (Possible: Argentina, Dominican Republic, Honduras)*
* Proposed AIDS vaccine efficacy trials (see "News Flashes").
Advertisement
phase I trial: first stage trial, focusing on safety and toxicity, very small cohort.
phase II trial: second stage trial, measures efficacy of vaccine in small cohort.
phase III trial: last stage of experimental testing, pivotal trial measures efficacy on a larger scale.
gp120: recombinant HIV envelope protein.
ALVAC-HIV: a recombinant canarypox virus expressing multiple HIV genes.
MVA-HIV: modified vaccinia Ankara (an attenuated vaccinia vector) expressing multiple HIV genes.
NYVAC-HIV: an attenuated vaccinia vector expressing multiple HIV genes.
TBC-3B: an attenuated vaccinia vector expressing multiple HIV genes.
This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.
This article was provided by Brown Medical School. It is a part of the publication HEPP News.
E-Mail
Printable Single-Page
Glossary
PDF
Share
